Last updated on August 2019

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments


Brief description of study

Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments

Clinical Study Identifier: NCT03056755

Find a site near you

Start Over

New Mexico Cancer Care Alliance

Albuquerque, NM United States
  Connect »

Mayo Clinic (Arizona)

Phoenix, AZ United States
  Connect »

Lahey Clinic

Burlington, MA United States
  Connect »

Beverly Hills Cancer Center

Beverly Hills, CA United States
  Connect »

USC Norris Cancer Center

Los Angeles, CA United States
  Connect »

Mercy Medical Center

Baltimore, MD United States
  Connect »

UT Health San Antonio

San Antonio, TX United States
  Connect »

Novartis Investigative Site

Montpellier Cedex 5, France
  Connect »

Novartis Investigative Site

Saint Herblain cedex, France
  Connect »

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Novartis Investigative Site

Hospitalet de LLobregat, Spain
  Connect »

Novartis Investigative Site

Edinburgh, United Kingdom
  Connect »

Novartis Investigative Site

Leicester, United Kingdom
  Connect »

Novartis Investigative Site

Nottingham, United Kingdom
  Connect »